MOG-stimulated autologous CD4+ T cells

MOG-stimulated autologous CD4+ T cells are an experimental cell therapy in which a patient’s own CD4+ T lymphocytes are collected, expanded ex vivo, and specifically stimulated with myelin oligodendrocyte glycoprotein (MOG) or MOG-derived peptides before reinfusion, with the aim of modulating CNS-directed autoimmunity. CD4+ T cells recognizing MOG are central to the pathogenesis of demyelinating diseases such as multiple sclerosis and MOG antibody-associated disease, where they contribute to inflammatory demyelination through cytokine production and T–B cell cooperation.[2] By expanding and reintroducing autologous MOG-stimulated CD4+ cells under controlled conditions, this modality is being investigated as a way to reshape antigen-specific T-cell responses—potentially inducing tolerance or altering pathogenic T-cell repertoires—rather than broadly suppressing immunity. This approach fits within the broader class of antigen-specific, autologous CD4+ T-cell adoptive therapies under early-stage clinical evaluation for autoimmune and inflammatory CNS disorders.[2][3]

Other names

autologous CD4+ T cells stimulated and expanded ex vivo by a MOG peptide modified by the introduction of a thioreductase motif into the flanking residues of the T cell epitope